pharma · Major Depressive Disorder (MDD), with or without Anxious Distress · Major Depressive Disorder (MDD) · SPTX
Seaport Therapeutics
Seaport Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker SPTX. Primary therapeutic focus areas include Major Depressive Disorder (MDD), with or without Anxious Distress,
Boston, USA HQ
68 Employees
Public company Type
SPTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 68
- Programs
- 3
- Drugs
- 3
- Patents
- 1
SPT-300-2024-204
Phase 2 · other · Major Depressive Disorder (MDD), with or without Anxious Distress
SPT-300-2024-204 for Major Depressive Disorder (MDD), with or without Anxious Distress is a Phase 2 program (other) at Seaport Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code SPT-300-2024-204
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Seaport Therapeutics
- Phase
- Phase 2
- Modality
- other
- Indication
- Major Depressive Disorder (MDD), with or without Anxious Distress
- Status
- active
- Trials
- 1